{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T03:31:09Z","timestamp":1794627069543,"version":"4.9.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22067014"],"award-info":[{"award-number":["22067014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.neuropharm.2025.110324","type":"journal-article","created":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T09:59:57Z","timestamp":1738490397000},"page":"110324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Novel chimeric peptides of endomorphin-2 and the active fragments of ghrelin exhibit blood-brain barrier permeability and central antinociceptive effects with reduced opioid-related side effects"],"prefix":"10.1016","volume":"269","author":[{"given":"Yongling","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songxia","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangquan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4984-9078","authenticated-orcid":false,"given":"Jie","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110324_bib1","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/548457","article-title":"Ghrelin and functional dyspepsia","author":"Akamizu","year":"2010","journal-title":"Int J Pept"},{"key":"10.1016\/j.neuropharm.2025.110324_bib2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.18869\/acadpub.ibj.21.2.114","article-title":"Ghrelin exerts analgesic effects through modulation of IL-10 and TGF-\u03b2 levels in a rat model of inflammatory pain","volume":"21","author":"Azizzadeh","year":"2017","journal-title":"Iran. Biomed. J."},{"key":"10.1016\/j.neuropharm.2025.110324_bib3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1139\/cjpp-2020-0218","article-title":"Ghrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats","volume":"99","author":"Baser","year":"2021","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110324_bib4","first-page":"81","article-title":"Central actions of endomorphins: new endogenous opioids","volume":"41","author":"Bihm","year":"1998","journal-title":"Proc. West. Pharmacol. Soc."},{"key":"10.1016\/j.neuropharm.2025.110324_bib5","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1177\/0023677218824382","article-title":"Retrobulbar sinus injection of doxorubicin is more efficient than lateral tail vein injection at inducing experimental nephrotic syndrome in mice: a pilot study","volume":"53","author":"Bohnert","year":"2019","journal-title":"Lab. Anim"},{"key":"10.1016\/j.neuropharm.2025.110324_bib6","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1111\/bph.15165","article-title":"Multifunctional opioid receptor agonism and antagonism by a novel macrocyclic tetrapeptide prevents reinstatement of morphine-seeking behaviour","volume":"177","author":"Brice-Tutt","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110324_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114308","article-title":"An insight into the multifunctional role of ghrelin and structure activity relationship studies of ghrelin receptor ligands with clinical trials","volume":"235","author":"Bukhari","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2025.110324_bib8","first-page":"482","article-title":"Engineering human spinal microphysiological systems to model opioid-induced tolerance","volume":"22","author":"Cai","year":"2023","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.neuropharm.2025.110324_bib9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm7009364","article-title":"Multi-target-directed ligands to combat neurodegenerative diseases","volume":"51","author":"Cavalli","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2025.110324_bib10","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(19)30430-1","article-title":"Perioperative opioid analgesia-when is enough too much? A review of opioid-induced tolerance and hyperalgesia","volume":"393","author":"Colvin","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2025.110324_bib11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuropharm.2019.03.006","article-title":"Bifunctional opioid receptor ligands as novel analgesics","volume":"151","author":"Cunningham","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110324_bib12","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1021\/acschemneuro.8b00150","article-title":"DARK classics in chemical neuroscience: morphine","volume":"9","author":"Devereaux","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110324_bib13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14728222.2019.1586882","article-title":"Current strategies toward safer mu opioid receptor drugs for pain management","volume":"23","author":"Ehrlich","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.neuropharm.2025.110324_bib14","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1139\/cjpp-2020-0668","article-title":"The active fragments of ghrelin cross the blood-brain barrier and enter the brain to produce antinociceptive effects after systemic administration","volume":"99","author":"Fan","year":"2021","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110324_bib15","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.neuropharm.2011.09.013","article-title":"Effects of neuropeptide FF system on CB\u2081 and CB\u2082 receptors mediated antinociception in mice","volume":"62","author":"Fang","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110324_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106335","article-title":"Novel dual-target \u03bc-opioid and TRPV1 ligands as potential pharmacotherapeutics for pain management","volume":"131","author":"Gao","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.neuropharm.2025.110324_bib17","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0196-9781(03)00160-8","article-title":"Ghrelin-induced feeding is dependent on nitric oxide","volume":"24","author":"Gaskin","year":"2003","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2025.110324_bib18","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.peptides.2009.03.012","article-title":"Central Neuropeptide S inhibits distal colonic transit through activation of central Neuropeptide S receptor in mice","volume":"30","author":"Han","year":"2009","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2025.110324_bib19","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.2174\/092986707782793880","article-title":"Endomorphin analogs","volume":"14","author":"Janecka","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2025.110324_bib20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.pharep.2017.09.004","article-title":"The role of Cortistatin-14 in the gastrointestinal motility in mice","volume":"70","author":"Jiang","year":"2018","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.neuropharm.2025.110324_bib21","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/45230","article-title":"Ghrelin is a growth-hormone-releasing acylated peptide from stomach","volume":"402","author":"Kojima","year":"1999","journal-title":"Nature"},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2025.110324_bib22","first-page":"93","article-title":"Purification and distribution of ghrelin: the natural endogenous ligand for the growth hormone secretagogue receptor","volume":"56","author":"Kojima","year":"2001","journal-title":"Horm. Res."},{"key":"10.1016\/j.neuropharm.2025.110324_bib23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejphar.2008.07.055","article-title":"Effect of centrally administered C75, a fatty acid synthase inhibitor, on gastric emptying and gastrointestinal transit in mice","volume":"595","author":"Li","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110324_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.170943","article-title":"Synergistic interaction between DAMGO-NH(2) and NOP01 in peripherally acting antinociception in two mouse models of formalin pain","volume":"161","author":"Li","year":"2023","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2025.110324_bib25","doi-asserted-by":"crossref","first-page":"G1350","DOI":"10.1152\/ajpgi.00493.2005","article-title":"Ghrelin acts on the dorsal vagal complex to stimulate pancreatic protein secretion","volume":"290","author":"Li","year":"2006","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.neuropharm.2025.110324_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.peptides.2016.07.006","article-title":"Study on the molecular mechanism of antinociception induced by ghrelin in acute pain in mice","volume":"83","author":"Liu","year":"2016","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2025.110324_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2014.08.045","article-title":"The improved blood-brain barrier permeability of endomorphin-1 using the cell-penetrating peptide synB3 with three different linkages","volume":"476","author":"Liu","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.neuropharm.2025.110324_bib28","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1021\/acs.jmedchem.8b01644","article-title":"N-terminal liver-expressed antimicrobial peptide 2 (LEAP2) region exhibits inverse agonist activity toward the ghrelin receptor","volume":"62","author":"M'Kadmi","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2025.110324_bib29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1006\/bbrc.2001.5553","article-title":"Structure-activity relationship of ghrelin: pharmacological study of ghrelin peptides","volume":"287","author":"Matsumoto","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2025.110324_bib30","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.molmet.2015.03.005","article-title":"Ghrelin","volume":"4","author":"M\u00fcller","year":"2015","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.neuropharm.2025.110324_bib31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.neulet.2014.06.058","article-title":"Analgesic tolerance and cross-tolerance to the cannabinoid receptors ligands hemopressin, VD-hemopressin(\u03b1) and WIN55,212-2 at the supraspinal level in mice","volume":"578","author":"Pan","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2025.110324_bib32","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/pr.112.007138","article-title":"Mu opioids and their receptors: evolution of a concept","volume":"65","author":"Pasternak","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2025.110324_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-51140-w","article-title":"Effects of ghrelin on pGSK-3\u03b2 and \u03b2-catenin expression when protects against neuropathic pain behavior in rats challenged with chronic constriction injury","volume":"9","author":"Peng","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110324_bib34","article-title":"Reporting animal research: explanation and elaboration for the ARRIVE guidelines 2.0","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.neuropharm.2025.110324_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20102475","article-title":"Effects of intracerebroventricular and intra-arcuate nucleus injection of ghrelin on pain behavioral responses and met-enkephalin and \u03b2-endorphin concentrations in the periaqueductal gray area in rats","volume":"20","author":"Pirzadeh","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110324_bib36","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/ACO.0000000000001190","article-title":"Pain treatment and prophylaxis on pain","volume":"35","author":"Raeder","year":"2022","journal-title":"Curr. Opin. Anaesthesiol."},{"key":"10.1016\/j.neuropharm.2025.110324_bib37","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.molmet.2018.09.007","article-title":"Ghrelin transport across the blood-brain barrier can occur independently of the growth hormone secretagogue receptor","volume":"18","author":"Rhea","year":"2018","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.neuropharm.2025.110324_bib38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0304-3940(02)01381-2","article-title":"Site-specific effects of ghrelin on the neuronal activity in the hypothalamic arcuate nucleus","volume":"341","author":"Riediger","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2025.110324_bib39","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/npp.2013.28","article-title":"Hypothalamic \u03ba-opioid receptor modulates the orexigenic effect of ghrelin","volume":"38","author":"Romero-Pic\u00f3","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110324_bib40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/jb\/mvr134","article-title":"Structure, regulation and function of ghrelin","volume":"151","author":"Sato","year":"2012","journal-title":"J. Biochem."},{"key":"10.1016\/j.neuropharm.2025.110324_bib41","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.lfs.2009.02.025","article-title":"Bi- or multifunctional opioid peptide drugs","volume":"86","author":"Schiller","year":"2010","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2025.110324_bib42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.peptides.2012.03.013","article-title":"Intracerebroventricular administration of neuronostatin delays gastric emptying and gastrointestinal transit in mice","volume":"35","author":"Su","year":"2012","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2025.110324_bib43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejmech.2015.11.028","article-title":"Multitarget opioid ligands in pain relief: new players in an old game","volume":"108","author":"Turnaturi","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2025.110324_bib44","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.2174\/0929867311320220002","article-title":"Endomorphin derivatives with improved pharmacological properties","volume":"20","author":"Varamini","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2025.110324_bib45","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/febs.14763","article-title":"Identifying the binding mechanism of LEAP2 to receptor GHSR1a","volume":"286","author":"Wang","year":"2019","journal-title":"FEBS J."},{"key":"10.1016\/j.neuropharm.2025.110324_bib46","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.neuropharm.2015.06.010","article-title":"Endomorphin-1 analogues (MELs) penetrate the blood-brain barrier and exhibit good analgesic effects with minimal side effects","volume":"97","author":"Wang","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110324_bib47","article-title":"Opposite effects of neuropeptide FF on central antinociception induced by endomorphin-1 and endomorphin-2 in mice","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2025.110324_bib48","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.neuropharm.2016.03.017","article-title":"Pharmacological characterization of EN-9, a novel chimeric peptide of endomorphin-2 and neuropeptide FF that produces potent antinociceptive activity and limited tolerance","volume":"108","author":"Wang","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110324_bib49","doi-asserted-by":"crossref","first-page":"10198","DOI":"10.1021\/acs.jmedchem.6b01181","article-title":"Structure-based optimization of multifunctional agonists for opioid and neuropeptide FF receptors with potent nontolerance forming analgesic activities","volume":"59","author":"Wang","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2025.110324_bib50","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.peptides.2013.03.004","article-title":"In vivo characterization of the effects of ghrelin on the modulation of acute pain at the supraspinal level in mice","volume":"43","author":"Wei","year":"2013","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2025.110324_bib51","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1210\/endo.141.11.7873","article-title":"The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion","volume":"141","author":"Wren","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2025.110324_bib52","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0304-3940(03)00748-1","article-title":"Acute antinociceptive tolerance and partial cross-tolerance to endomorphin-1 and endomorphin-2 given intrathecally in the mouse","volume":"348","author":"Wu","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2025.110324_bib53","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0022-3565(24)29236-3","article-title":"Acute antinociceptive tolerance and asymmetric cross-tolerance between endomorphin-1 and endomorphin-2 given intracerebroventricularly in the mouse","volume":"299","author":"Wu","year":"2001","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110324_bib54","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1213\/ANE.0000000000006266","article-title":"OCP002, a mixed agonist of opioid and cannabinoid receptors, produces potent antinociception with minimized side effects","volume":"136","author":"Xu","year":"2023","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.neuropharm.2025.110324_bib55","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.21873\/invivo.13548","article-title":"Ghrelin induces the production of hypothalamic NPY through the AMPK-mTOR pathway to alleviate cancer-induced bone pain","volume":"38","author":"Xu","year":"2024","journal-title":"In Vivo"},{"key":"10.1016\/j.neuropharm.2025.110324_bib56","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/386499a0","article-title":"A potent and selective endogenous agonist for the mu-opiate receptor","volume":"386","author":"Zadina","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2025.110324_bib57","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neuropharm.2015.12.024","article-title":"Endomorphin analog analgesics with reduced abuse liability, respiratory depression, motor impairment, tolerance, and glial activation relative to morphine","volume":"105","author":"Zadina","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110324_bib58","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1021\/acschemneuro.2c00442","article-title":"OFP011 cyclic peptide as a multifunctional agonist for opioid\/neuropeptide FF receptors with improved blood-brain barrier penetration","volume":"13","author":"Zhang","year":"2022","journal-title":"ACS Chem. Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825000309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825000309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:21:29Z","timestamp":1777350089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825000309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":58,"alternative-id":["S0028390825000309"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110324","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel chimeric peptides of endomorphin-2 and the active fragments of ghrelin exhibit blood-brain barrier permeability and central antinociceptive effects with reduced opioid-related side effects","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110324","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110324"}}